000 | 01976ngm a2200421 a 4500 | ||
---|---|---|---|
001 | HST5396 | ||
003 | UkLoHST | ||
006 | m c | ||
007 | cr|cna|||a|||| | ||
007 | vz|czazum | ||
008 | 211104s2021 enk|||||||||||s|||v|eng d | ||
028 | 5 | 0 |
_a5396 _bHenry Stewart Talks |
035 | _a(UkLoHST)4728 | ||
040 |
_aUkLoHST _beng _cUkLoHST |
||
100 | 1 |
_aInderberg, Else Marit, _u(The Norwegian Radium Hospital, Norway) _4spk |
|
245 | 1 | 0 |
_aLatest advances in the development of CAR & TCR T-cell treatments for solid tumours _h[electronic resource] / _cElse Marit Inderberg. |
260 |
_aLondon : _bHenry Stewart Talks, _c2021. |
||
300 |
_a1 online resource (1 streaming video file (28 min.) : _bcolor, sound). |
||
490 | 1 |
_aPeriodic reports : advances in clinical interventions and research platforms, _x2056-452X |
|
500 | _aAnimated audio-visual presentation with synchronized narration. | ||
500 | _aTitle from title frames. | ||
505 | 0 | _aContents: Cancer immunity and adoptive cell therapy -- CAR-T and TCR-based therapy treating solid tumours -- Examples in osteosarcoma and colon cancer -- Transient CAR or TCR expression for safety evaluation -- Factors affecting in vivo efficacy and T-cell persistence -- A universal allogeneic therapeutic product. | |
506 | _aAccess restricted to subscribers. | ||
538 | _aMode of access: World Wide Web. | ||
650 | 0 |
_aCancer _xImmunotherapy. |
|
650 | 2 | _aCell- and Tissue-Based Therapy. | |
650 | 2 |
_aColonic Neoplasms _xtherapy. |
|
650 | 2 | _aCytotoxicity, Immunologic. | |
650 | 2 | _aImmunotherapy, Adoptive. | |
650 | 2 |
_aNeoplasms _ximmunology. |
|
650 | 2 |
_aOsteosarcoma _xtherapy. |
|
650 | 2 | _aReceptors, Antigen, T-Cell. | |
650 | 2 | _aReceptors, Chimeric Antigen. | |
650 | 2 | _aT-Lymphocytes. | |
830 | 0 |
_aHenry Stewart talks. _pBiomedical & life sciences collection. _pPeriodic reports. |
|
856 | 4 | 0 | _uhttps://hstalks.com/bs/4728/ |
856 | 4 | 2 |
_uhttps://hstalks.com/bs/p/1048/ _3Series |
999 |
_c75656 _d75656 |